ramucirumab + S-1 + cisplatin

This is a combination therapy consisting of **ramucirumab**, a monoclonal antibody targeting **vascular endothelial growth factor receptor 2 (VEGFR2)**, **S-1**, an oral fluoropyrimidine that combines tegafur (a prodrug of 5-fluorouracil), gimeracil, and oteracil, and **cisplatin**, a platinum-based chemotherapy agent. Ramucirumab works by inhibiting angiogenesis essential for tumor growth, while S-1 and cisplatin act as cytotoxic agents inhibiting DNA synthesis and function. This regimen has been studied in phase 1b trials in chemotherapy-naïve patients with metastatic gastric or gastroesophageal junction cancer, showing general tolerability and preliminary anti-tumor activity[3]. The precise combination of ramucirumab + S-1 + cisplatin is designed to synergistically inhibit tumor proliferation in advanced or metastatic gastric cancer.

Brand names

Cyramza (ramucirumab)None for S-1 + cisplatin combination